Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells.
about
Acetylation of cyclin T1 regulates the equilibrium between active and inactive P-TEFb in cellsSuberoylanilide hydroxamic acid reactivates HIV from latently infected cellsAn in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patientsA Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.Prospects for treatment of latent HIV.Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activationNovel HIV-1 knockdown targets identified by an enriched kinases/phosphatases shRNA library using a long-term iterative screen in Jurkat T-cellsAdvancements in Developing Strategies for Sterilizing and Functional HIV Cures.Combinatorial latency reactivation for HIV-1 subtypes and variantsBET bromodomain inhibition as a novel strategy for reactivation of HIV-1Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaBPharmaceutical approaches to eradication of persistent HIV infection.Gene silencing in HIV-1 latency by polycomb repressive group.T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway.Selective HDAC inhibition for the disruption of latent HIV-1 infection.Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.Quantitative evaluation and optimization of co-drugging to improve anti-HIV latency therapyCNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies.Targeting HIV latency: pharmacologic strategies toward eradication.HIV-1 transcription and latency: an update.Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling.The challenge of finding a cure for HIV infection.Regulation of HIV-1 transcription at 3% versus 21% oxygen concentrationHIV type-1 latency: targeted induction of proviral reservoirs.Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.Curing HIV: Pharmacologic approaches to target HIV-1 latency.Lost in transcription: molecular mechanisms that control HIV latencyEliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials.An integrated overview of HIV-1 latency.HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.Making a Short Story Long: Regulation of P-TEFb and HIV-1 Transcriptional Elongation in CD4+ T Lymphocytes and Macrophages.Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions.HIV-1 endocytosis in astrocytes: a kiss of death or survival of the fittest?Role of Host Factors on the Regulation of Tat-Mediated HIV-1 Transcription.Progress and challenges in the use of latent HIV-1 reactivating agentsLandscape review of current HIV 'kick and kill' cure research - some kicking, not enough killing.Exosomes from uninfected cells activate transcription of latent HIV-1.Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription.Selected drugs with reported secondary cell-differentiating capacity prime latent HIV-1 infection for reactivation.
P2860
Q24318644-E06FF04E-7A42-4F95-A899-C9F8408803DBQ24644201-B78A03DF-5A12-4312-9E33-DE09751F5AD4Q28538015-F3AC3D5B-87B3-4BF0-B722-1E00A0EC633EQ30385378-A3A10826-E0BE-4C47-9F9A-3127EC658984Q30424413-8F5808EC-C631-4F99-9EAB-603006B13ADAQ33476165-E1E8D9EC-BE87-42F3-A6A1-F1D7EFF7C1ABQ33508788-2FD230F7-9D67-4948-933F-04DBAE400F19Q33533377-734A6EB9-EF26-4AEF-AF29-36FB4324BEF1Q33654409-2B5DC2F7-2E1E-47BD-9B83-70C9E3DBAF11Q33877492-54FEE3ED-C15B-4290-9E52-38820A15D5B5Q34032827-A67EDCA3-9397-4B41-AB80-8432795FA066Q34482017-248B6FCE-0E50-4175-A22B-A81301FF9890Q34941973-FF9DC10A-FCDD-4C35-ADCD-15A44E2C9E74Q34980577-F16CF95B-5BF0-4C12-B879-5414A80D49E2Q35113716-F25F3DD9-49E6-4AF2-B27C-F7DF16F16E9AQ35227888-7A6D95E8-6327-479E-9A2B-AF2A512CF768Q35720063-2AD4573D-6657-4E0C-A31B-F433FB9EC6BDQ35848096-725727A2-28B8-4EB8-B683-95E9893014D3Q36719187-F4E91421-9482-47AD-9C8A-4A40167D6EE7Q36901950-CF6525FC-FBDD-4EA5-BCB9-EC7697DB601AQ36976156-06B002DD-5681-4883-81A6-5FF714E125FDQ37041173-5EFB8E8B-5CE5-4E13-BBC1-A0C577B67249Q37407598-3DF0C10C-6C03-445B-A27B-034FA5422FEDQ37423506-9B8B5D2F-9548-4140-90BA-5C43D80A1E7BQ37502488-E7FC6D62-8079-40CA-BFE9-90600F9DAAD3Q37644561-2EFDA939-C4F1-44F0-9F97-32E713005F49Q37645582-C996FB51-E4C2-46D1-9461-92E7167557C0Q38091888-3FF7CE56-ECB8-4ED3-BB55-947FAE729712Q38096822-845803BB-AECF-440C-9DC6-73EDD20AB3DAQ38163449-C21B2BD6-A72D-4CED-8E24-B9B619CF0970Q38204866-BA2A5F86-4837-486B-936B-54F9A7CB2258Q38212042-5B552DC8-3701-41C8-A1E3-5A08DADC88ECQ38246141-D9DD440E-484E-44BB-BCD3-C552C5C4EF66Q38248964-990A1756-949F-49CB-A904-B14BEFF71AB5Q38430337-DCBA23A8-C13F-47AE-83F6-4056E11E1798Q38509230-2DAF4790-FC1D-4080-9B36-71B566095C51Q38636019-7769D3F1-FC77-4AF2-941B-EAC64A52746BQ38702490-091A3DD1-AFBE-4DAA-89FE-2C5CBB8CF6E0Q39173861-0D77D665-2582-45B8-8DF2-48FF76304B4CQ39331564-B4946DF9-93C3-4144-A1C6-F22191B16451
P2860
Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Hexamethylbisacetamide and dis ...... cy virus type 1 latency in CD4
@nl
Hexamethylbisacetamide and dis ...... e 1 latency in CD4(+) T cells.
@en
type
label
Hexamethylbisacetamide and dis ...... cy virus type 1 latency in CD4
@nl
Hexamethylbisacetamide and dis ...... e 1 latency in CD4(+) T cells.
@en
prefLabel
Hexamethylbisacetamide and dis ...... cy virus type 1 latency in CD4
@nl
Hexamethylbisacetamide and dis ...... e 1 latency in CD4(+) T cells.
@en
P2860
P356
P1476
Hexamethylbisacetamide and dis ...... e 1 latency in CD4(+) T cells.
@en
P2093
Nancy M Archin
Shailesh K Choudhary
P2860
P304
P356
10.1086/529525
P407
P577
2008-04-01T00:00:00Z